Abbvie Inc (NYSE: ABBV) is 24.80% higher on its value in year-to-date trading and has touched a low of $135.85 and a high of $193.91 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The ABBV stock was last observed hovering at around $193.00 in the last trading session, with the day’s gains setting it 0.4%.
Currently trading at $193.40, the stock is 5.13% and 10.57% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 4.72 million and changing 0.21% at the moment leaves the stock 17.09% off its SMA200. ABBV registered 27.14% gain for a year compared to 6-month gain of 10.88%.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a 10.34% loss in the last 1 month and extending the period to 3 months gives it a 18.08%, and is 1.58% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 1.58% over the week and 2.52% over the month.
Abbvie Inc (ABBV) has around 50000 employees, a market worth around $341.61B and $55.00B in sales. Current P/E ratio is 64.69 and Fwd P/E is 15.98. Profit margin for the company is 9.63%. Distance from 52-week low is 42.36% and -0.26% from its 52-week high. The company has generated returns on investments over the last 12 months (8.17%).
Abbvie Inc quarterly earnings per share for the current quarter are estimated at 2.95 with sales reaching $14.27B over the same period.The EPS is expected to shrink by -2.12% this year, but quarterly earnings will post 2.60% year-over-year. Quarterly sales are estimated to grow 4.10% in year-over-year returns.
4142.0 institutions hold shares in Abbvie Inc (ABBV), with institutional investors hold 73.46% of the company’s shares. The shares outstanding are 1.77B, and float is at 1.76B with Short Float at 0.99%. Institutions hold 73.39% of the Float.
The top institutional shareholder in the company is VANGUARD GROUP INC with over 170.38 million shares valued at $$31.03 billion. The investor’s holdings represent 9.6312 of the ABBV Shares outstanding. As of 2024-03-31, the second largest holder is BLACKROCK INC. with 142.96 million shares valued at $$26.03 billion to account for 8.0814 of the shares outstanding. The other top investors are STATE STREET CORP which holds 77.97 million shares representing 4.4076 and valued at over $$14.2 billion, while JPMORGAN CHASE & CO holds 2.8976 of the shares totaling 51.26 million with a market value of $$9.33 billion.
Abbvie Inc (ABBV) Insider Activity
Abbvie Inc disclosed in a document filed with the SEC on Aug 05 ’24 that GONZALEZ RICHARD A (EXECUTIVE CHAIRMAN OF BOARD) sold a total of 66,500 shares of the company’s common stock. The trade occurred on Aug 05 ’24 and was made at $186.52 per share for $12.4 million. Following the transaction, the insider now directly holds 0.45 million shares of the ABBV stock.
Still, SEC filings show that on Aug 07 ’24, Hudson Thomas J (Officer) Proposed Sale 101,886 shares at an average price of $187.62 for $19.12 million. The insider now directly holds shares of Abbvie Inc (ABBV).
